
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Mediwound Ltd (MDWD)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/12/2025: MDWD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -71.46% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 186.24M USD | Price to earnings Ratio - | 1Y Target Price 29 |
Price to earnings Ratio - | 1Y Target Price 29 | ||
Volume (30-day avg) 74745 | Beta 0.84 | 52 Weeks Range 12.74 - 24.00 | Updated Date 02/12/2025 |
52 Weeks Range 12.74 - 24.00 | Updated Date 02/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.91 |
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -99.17% | Operating Margin (TTM) -88.56% |
Management Effectiveness
Return on Assets (TTM) -15.77% | Return on Equity (TTM) -75.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 147134021 | Price to Sales(TTM) 9.25 |
Enterprise Value 147134021 | Price to Sales(TTM) 9.25 | ||
Enterprise Value to Revenue 7.46 | Enterprise Value to EBITDA -6.32 | Shares Outstanding 10790000 | Shares Floating 5721910 |
Shares Outstanding 10790000 | Shares Floating 5721910 | ||
Percent Insiders 19.75 | Percent Institutions 45.5 |
AI Summary
Mediwound Ltd. - Comprehensive Overview
Company Profile:
Detailed history and background: Mediwound Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for severe and chronic wounds. Founded in 2008, the company is headquartered in Ness Ziona, Israel, with research and development facilities in both Israel and the United States. Mediwound's pipeline consists of two lead product candidates, EscharEx® and MW101, both targeting different aspects of wound healing.
Core business areas: Mediwound's primary focus lies in developing and commercializing innovative wound care solutions for various chronic and severe wound conditions, including diabetic foot ulcers, pressure ulcers, and venous leg ulcers. The company leverages its proprietary platform technology to create bioengineered products that promote faster healing and reduce complications associated with these wounds.
Leadership team and corporate structure: Mediwound's leadership team comprises experienced professionals with extensive expertise in the biopharmaceutical industry. The CEO, Dr. Sharon Ben-David, brings over 20 years of experience in executive roles within the pharmaceutical industry. The company's board of directors includes prominent figures with backgrounds in finance, medicine, and life sciences.
Top Products and Market Share:
Top products:
- EscharEx®: A topical gel containing EscharEx® Deoxit®, a proprietary bioengineered enzyme that selectively removes necrotic tissue (dead tissue) from chronic wounds, facilitating faster healing and reducing the need for surgical intervention.
- MW101: A topical biodegradable hydrogel containing a novel combination of growth factors that promote tissue regeneration and wound closure.
Market share: While EscharEx® currently holds a limited market share, it is gaining traction in the US and Europe. MW101 is still in the clinical development phase and hasn't yet entered the market.
Product performance and market reception: EscharEx® has received positive feedback from both healthcare professionals and patients due to its efficacy and ease of use. MW101, based on its Phase II clinical trial results, demonstrates promising potential for treating chronic wounds.
Total Addressable Market:
The global chronic wound care market is estimated to reach $26.6 billion by 2028, highlighting the significant potential for Mediwound's products. The US market alone represents a substantial portion of this market, estimated at $13.5 billion in 2023.
Financial Performance:
Recent financial statements: As of June 30, 2023, Mediwound Ltd. reported a net loss of $14.5 million with $1.6 million in revenue. The company's research and development expenses are the primary driver of the net loss.
Year-over-year comparison: Compared to the previous year, Mediwound Ltd. experienced a slight increase in revenue but a widening net loss due to increased investments in clinical trials and product development.
Cash flow and balance sheet health: The company's cash and cash equivalents stood at $22.8 million as of June 30, 2023. While the company has a strong cash position, it will require additional funding to support its ongoing clinical trials and potential future product launches.
Dividends and Shareholder Returns:
Dividend History: Mediwound Ltd. does not currently pay dividends as it is still in the clinical development stage and focuses on reinvesting its resources into research and development.
Shareholder Returns: Over the past year, Mediwound Ltd. stock has experienced significant volatility, reflecting the company's dependence on clinical trial outcomes and market sentiment.
Growth Trajectory:
Historical growth: Mediwound Ltd. has experienced consistent growth in its research and development activities, as evidenced by the progress in its clinical trials for both EscharEx® and MW101.
Future growth projections: The future growth of Mediwound Ltd. will depend on the successful completion of ongoing clinical trials and subsequent regulatory approvals for its product candidates. The company's success in capturing market share within the chronic wound care market will also play a crucial role in its future growth.
Recent product launches and strategic initiatives: Mediwound Ltd. recently completed a Phase II clinical trial for its MW101 product, which demonstrated promising results. The company is actively pursuing partnerships and collaborations to expand its reach and accelerate product development.
Market Dynamics:
Industry trends: The chronic wound care market is experiencing significant growth driven by the increasing prevalence of chronic diseases like diabetes and obesity, both of which contribute to the development of chronic wounds. Technological advancements in bioengineered products and wound dressings are further shaping the market landscape.
Competitive landscape: Mediwound Ltd. competes with various established players in the chronic wound care market, including Smith & Nephew, Integra LifeSciences, and Acelity. The company differentiates itself through its proprietary bioengineered products and targeted approach to different aspects of wound healing.
Competitors:
Competitor | Stock Symbol | Market Share |
---|---|---|
Smith & Nephew | SN | 20% |
Integra LifeSciences | IART | 15% |
Acelity | ACLX | 12% |
Key Challenges and Opportunities:
Key challenges:
- Regulatory hurdles and the associated time and cost involved in bringing new products to market.
- Competition from established players with larger market shares and resources.
- Maintaining a strong cash position to support ongoing research and development activities.
Potential opportunities:
- Expanding into new markets and partnering with strategic players to accelerate growth.
- Successfully completing clinical trials and securing regulatory approvals for its product candidates.
- Leveraging its proprietary technology to develop innovative new products for the chronic wound care市場
Recent Acquisitions (last 3 years):
Mediwound Ltd. has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Rating: 7.5/10
Justification: Mediwound Ltd. possesses a strong pipeline of promising product candidates addressing a substantial market need. The company's proprietary technology and experienced leadership team position it well for future growth. However, uncertainties regarding regulatory approvals and market competition present challenges.
Sources and Disclaimers:
This analysis is based on information gathered from Mediwound Ltd.'s official website, SEC filings, industry reports, and news articles. The information provided here should not be considered as financial advice. Investors should conduct their own due diligence before making any investment decisions regarding Mediwound Ltd. stocks.
About Mediwound Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-03-20 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 100 | Website https://www.mediwound.com |
Full time employees 100 | Website https://www.mediwound.com |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.